Short Interest in Aridis Pharmaceuticals Inc (NASDAQ:ARDS) Rises By 26.9%

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 16,500 shares, an increase of 26.9% from the May 30th total of 13,000 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 4,000 shares, the short-interest ratio is currently 4.1 days.

ARDS has been the subject of several recent research reports. Northland Securities reaffirmed a “buy” rating and issued a $100.00 price target on shares of Green Dot in a report on Wednesday, April 17th. Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 16th. Finally, Zacks Investment Research lowered Green Plains from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 27th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Aridis Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $27.50.

ARDS stock opened at $9.75 on Friday. Aridis Pharmaceuticals has a 1-year low of $6.91 and a 1-year high of $13.85. The firm has a 50 day moving average of $9.42.

Aridis Pharmaceuticals (NASDAQ:ARDS) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.12). Aridis Pharmaceuticals had a negative net margin of 660.78% and a negative return on equity of 1,961.31%. The company had revenue of $1.02 million during the quarter. On average, sell-side analysts predict that Aridis Pharmaceuticals will post -3.11 earnings per share for the current year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with's FREE daily email newsletter.